Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 May 7;125(19):3024-31.
doi: 10.1182/blood-2015-01-623991. Epub 2015 Mar 26.

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

Shannon R McCurdy  1 , Jennifer A Kanakry  1 , Margaret M Showel  1 , Hua-Ling Tsai  1 , Javier Bolaños-Meade  1 , Gary L Rosner  1 , Christopher G Kanakry  1 , Karlo Perica  1 , Heather J Symons  1 , Robert A Brodsky  1 , Douglas E Gladstone  1 , Carol Ann Huff  1 , Keith W Pratz  1 , Gabrielle T Prince  1 , Amy E Dezern  1 , Ivana Gojo  1 , William H Matsui  1 , Ivan Borrello  1 , Michael A McDevitt  1 , Lode J Swinnen  1 , B Douglas Smith  1 , Mark J Levis  1 , Richard F Ambinder  1 , Leo Luznik  1 , Richard J Jones  1 , Ephraim J Fuchs  1 , Yvette L Kasamon  1
Affiliations

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

Shannon R McCurdy et al. Blood. .

Abstract

Related HLA-haploidentical blood or marrow transplantation (BMT) with high-dose posttransplantation cyclophosphamide (PTCy) is being increasingly used because of its acceptable safety profile. To better define outcomes of nonmyeloablative (NMA) HLA-haploidentical BMT with PTCy, 372 consecutive adult hematologic malignancy patients who underwent this procedure were retrospectively studied. Risk-stratified outcomes were evaluated using the refined Disease Risk Index (DRI), developed to stratify disease risk across histologies and allogeneic BMT regimens. Patients received uniform conditioning, T-cell-replete allografting, then PTCy, mycophenolate mofetil, and tacrolimus. Six-month probabilities of nonrelapse mortality and severe acute graft-versus-host disease were 8% and 4%. With 4.1-year median follow-up, 3-year probabilities of relapse, progression-free survival (PFS), and overall survival (OS) were 46%, 40%, and 50%, respectively. By refined DRI group, low (n = 71), intermediate (n = 241), and high/very high (n = 60) risk groups had 3-year PFS estimates of 65%, 37%, and 22% (P < .0001), with corresponding 3-year OS estimates of 71%, 48%, and 35% (P = .0001). On multivariable analyses, the DRI was statistically significantly associated with relapse, PFS, and OS (each P < .001). This analysis demonstrates that the DRI effectively risk stratifies recipients of NMA HLA-haploidentical BMT with PTCy and also suggests that this transplantation platform yields similar survivals to those seen with HLA-matched BMT.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall outcomes of NMA haplo BMT with high-dose posttransplantation cyclophosphamide. (A) Progression-free and overall survival. (B-D) Cumulative incidences by competing-risk analysis of relapse and nonrelapse mortality (B), acute graft-versus-host disease (C), and any chronic graft-versus-host disease (D). Point estimates are provided in Table 2.
Figure 2
Figure 2
Risk-stratified outcomes of NMA haplo BMT based on refined DRI group. (A) Progression-free survival. (B) Overall survival. (C) Cumulative incidence of relapse. (D) Cumulative incidence of nonrelapse mortality. Point estimates are provided in Table 2. Int., intermediate; V, very.
Figure 3
Figure 3
Disease-specific relapse risks. Cumulative incidences by competing-risk analysis of relapse in intermediate-risk aggressive NHL (n = 84) (A) and relapse in intermediate-risk AML (n = 64) (B) based on refined DRI grouping.
See this image and copyright information in PMC

References

    1. Brunstein CG, Fuchs EJ, Carter SL, et al. Blood and Marrow Transplant Clinical Trials Network. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011;118(2):282–288. - PMC - PubMed
    1. Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med. 1985;313(13):765–771. - PubMed
    1. Petersdorf EW, Gooley TA, Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood. 1998;92(10):3515–3520. - PubMed
    1. Morishima Y, Sasazuki T, Inoko H, et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood. 2002;99(11):4200–4206. - PubMed
    1. Szydlo R, Goldman JM, Klein JP, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol. 1997;15(5):1767–1777. - PubMed

Publication types

MeSH terms

Substances